← All trials
NCT00394329
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2006
- Primary completion
- Dec 1, 2011
- Completion date
- Dec 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 288
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Pennsylvania State UniversityLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of WisconsinOverall official - principal investigator
- Kaiser PermanenteOverall official - principal investigator
- University of ArizonaOverall official - principal investigator
- University of DenverStudy chair
- Washington University in St. LouisOverall official - principal investigator
- Pennsylvania State UniversityOverall official - principal investigator
- Pennsylvania State UniversityReponsible party - principal investigator
- University of Colorado, DenverOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.